HWM
GANX icon

HB Wealth Management’s Gain Therapeutics GANX Stock Holding History

HB Wealth Management’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.9K Buy
+12,783
New +$23.6K ﹤0.01% 1693

Other funds holding GANX

GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BFA
Benedict Financial Advisors Atlanta, Georgia $515M AUM 24.59% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

HB Wealth Management's GANX Position: Q2 2026 in Review

HB Wealth Management opened a new position in Gain Therapeutics (GANX) in Q2 2026: 12,783 shares worth $25.9K. The stake represents ﹤0.01% of the portfolio and ranks #1693 among its holdings.

10 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • HB Wealth Management held 12,783 shares of Gain Therapeutics worth $25.9K as of Q2 2026.
  • Gain Therapeutics was a new HB Wealth Management position in Q2 2026.
  • Gain Therapeutics made up ﹤0.01% of HB Wealth Management's portfolio in Q2 2026, its #1693 holding.
  • 10 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.